학술논문
[177 Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Document Type
Article
Author
Emmett, L.; Crumbaker, M.; Nguyen, A.; Joshua, A.M.; Lin, P.; Subramaniam, S.; Zhang, A.Y.; Yip, S.; Thomas, H.; Langford, A.; Martin, A.J.; Stockler, M.R.; Weickhardt, A.; Lee, S.-T.; Sandhu, S.; Hofman, M.S.; Ng, S.; Francis, R.J.; Redfern, A.D.; Macdonald, W.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; Gedye, C.; Rutherford, N.K.; Kumar, A.R.; Pook, D.; Ramdave, S.; Nadebaum, D.P.; Voskoboynik, M.; Krieger, L.; Schembri, G.; Chua, W.; Horvath, L.; Bastick, P.; Butler, P.; McJannett, M.; Davis, I.D.
Source
In: The Lancet Oncology . (The Lancet Oncology, May 2024, 25(5):563-571)
Subject
Language
English
ISSN
14745488
14702045
14702045